NCT01340508Unknown2 期
A Phase II Trial of Preoperative Concurrent Chemotherapy and (IMRT) in Locally Advanced Rectal Cancer
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 63
- 试验地点
- 2
- 主要终点
- Pathological complete response rates
研究概览
简要总结
The hypothesis of this study is that dose escalated intensity modulated radiotherapy (IMRT) to a dose of 55Gy in 25# to primary rectal tumor concurrent with oral capecitabine results in an improved pathological response rate from 8% (German trial) to 25%.
详细描述
This study aims to look at whether radiation dose escalation with intensity modulated radiotherapy can increase the rates of pathological complete response in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pathologically proven diagnosis of adenocarcinoma of the rectum
- •Clinically determined to be stage T3 or T4,N0-N2, and M0 -staged by MRI or transrectal ultrasound of the rectum
- •Patients who are medically operable and who have resectable adenocarcinoma of the rectum at least <15cm from the anal verge
- •Adequate liver/renal and haematological function.
- •Eastern Cooperative Oncology Group (ECOG) performance 0-2
- •Age ≥ 18 years
- •Full blood count obtained within 2 weeks prior to registration on study, with adequate bone marrow function defined as follows:
- •Absolute neutrophil count (ANC) ≥ 1,800 cells/mm3
- •Platelets ≥ 100,000 cells/mm3
- •Haemoglobin ≥ 8.0 g/dl
- •Serum creatinine within normal institutional limits or creatinine clearance ≥ 50 ml/min
- •Bilirubin within normal institutional limits
- •AST and ALT < 2.5 x the IULN
- •Patient must sign study specific informed consent prior to study entry
排除标准
- •Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years
- •Prior systemic chemotherapy for colorectal cancer; note that prior chemotherapy for a different cancer is allowable.
- •Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
- •Severe, active comorbidity, defined as follows:
- •Unstable angina and/or congestive heart failure requiring hospitalization within the last 12 months
- •Transmural myocardial infarction within the last 6 months
- •Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects
- •Acquired immune deficiency syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol.
- •Evidence of uncontrolled seizures, central nervous system disorders, or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance of oral drug intake.
- •Known, existing uncontrolled coagulopathy. Patients on therapeutic anticoagulation may be enrolled provided that they have been clinically stable on anti-coagulation for at least 2 weeks.
- •Major surgery within 28 days of study enrollment (other than diverting colostomy)
- •Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic
- •Prior allergic reaction to capecitabine
- •Any evidence of distant metastases (M1)
- •A synchronous primary colon carcinoma
- •Extension of malignant disease into the anal canal
- •Lack of physical integrity of the gastrointestinal tract (i.e., severe Crohn's disease that results in
- •malabsorption; significant bowel resection that would make one concerned about the absorption of capecitabine) or malabsorption syndrome that would preclude feasibility of oral chemotherapy (capecitabine)
- •Participation in any investigational drug study within 28 days of study enrollment
结局指标
主要结局
Pathological complete response rates
时间窗: 8 weeks post chemoradiotherapy
Pathogical complete response rate 8 weeks post chemoradiotherapy at surgery according to Ryan's classification
次要结局
- Toxicity(2 years)
- Disease Free survival(2 years)
- Downstaging rates(8 weeks after chemoradiotherapy)
- Sphincter Preservation rates(8 weeks after chemoradiotherapy)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
2 期
A Study for Short Preoperative Chemoradiotherapy for Resectable Rectal CarcinomaChemoradiotherapyNCT00973778Shanghai Jiao Tong University School of Medicine62
已完成
2 期
The Role of Induction Chemotherapy for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRTNasopharyngeal NeoplasmsNCT01797900Chinese Academy of Medical Sciences130
已完成
不适用
A phase I dose escalation study of concurrent chemoradiotherapy in patients with unresectable hepatocellular carcinomaNeoplasmsKCT0002644Yonsei University Health System, Gangnam Severance Hospital17
Unknown
2 期
Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal CancerAnal CancerNCT03381352Chinese Academy of Medical Sciences27
已完成
不适用
Preoperative Chemo-radiation With IG-IMRT Dose Escalation for Locally Advanced Rectal CancersAdvanced Rectal CancersNCT03200249Centre Georges Francois Leclerc15